Medtronic (MDT) EBT Margin (2014 - 2026)

Medtronic (MDT) posted EBT Margin of 18.7% for Q2 2026, up 20.1% sequentially from 15.57% in Q1 2026, and up 458.0% YoY from 3.35% in Q2 2025.

Medtronic (MDT) EBT Margin (2014 - 2026) Analysis & Trends

Medtronic has reported EBT Margin for 13 years, with the latest figure at 18.7% in Q2 2026.

Quarterly EBT Margin rose 458.0% year-over-year to 18.7% in Q2 2026, while the trailing twelve-month figure through Apr 2026 was 16.88% (up 10.0% YoY) and the FY2026 annual result came in at 16.87%, up 9.0% from the prior year.
EBT Margin improved to 18.7% in Q2 2026 per MDT's latest filing, from 15.57% in the prior quarter.
Over five years, EBT Margin peaked at 20.47% in Q1 2022 and troughed at 9.95% in Q2 2024.
A 5-year average of 16.86% and a median of 17.81% in 2025 frame the typical range for EBT Margin.
The sharpest annual moves came in 2022 and 2024: EBT Margin surged 478 bps in 2022, then tumbled 820 bps in 2024.
Over 5 years, EBT Margin stood at 18.39% in 2022, then decreased by 11 bps to 16.45% in 2023, then rose by 13 bps to 18.55% in 2024, then dropped by 4 bps to 17.82% in 2025, then rose by 5 bps to 18.7% in 2026.
According to Business Quant data, EBT Margin over the past three periods registered 18.7%, 15.57%, and 17.82% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Abbott Laboratories	200.08 Bn	194.48 Bn	7.27 Bn	12.10%
2	Stryker	129.71 Bn	126.23 Bn	4.50 Bn	23.74%
3	Medtronic	120.07 Bn	110.85 Bn	6.41 Bn	18.70%
4	Boston Scientific	74.08 Bn	73.54 Bn	3.85 Bn	19.48%
5	Edwards Lifesciences	52.68 Bn	48.43 Bn	1.35 Bn	29.86%
6	Dexcom	34.51 Bn	32.56 Bn	830.00 Mn	24.27%
7	GE HealthCare Technologies	34.03 Bn	31.92 Bn	2.18 Bn	13.09%
8	Koninklijke Philips	26.51 Bn	23.19 Bn	4.55 Bn	8.91%
9	Steris	23.20 Bn	22.72 Bn	684.20 Mn	18.32%
10	Zimmer Biomet Holdings	19.37 Bn	18.96 Bn	1.54 Bn	11.72%

Download Data